Wise Investments

[Scrooge McDuck]

EVSC, one for the radar, maybe more......
At .29, I see a bottom/bounce at .09, but the Bollinger Bands are starting to come together and today's news could make it bounce earlier.

October 8, 2003

MONTGOMERY, Texas, Oct 8, 2003 (BUSINESS WIRE) --

Endovasc Inc. (OTCBB:EVSC - News), an early-stage drug development company that pioneers new cardiovascular and metabolic drug therapies, announced today that it has received approval from the Republic of Georgia's Ministry of Health and the Ethics Committee at the Georgian Angiology and Vascular Center located in Thilisi, Georgia to commence enrollment of patients in its multicenter clinical trial for Liprostin(TM).

The Georgian Angiology and Vascular Center is the first of eight sites to begin enrolling patients in Endovasc's 120 patient, open-label, multi-center study of Liprostin(TM) for patients who suffer from critical limb ischemia (CLI) and intermittent claudication (leg pain), but do not require angioplasty. The other seven sites, located in Brazil, Mexico and Eastern Europe, are expected to begin enrolling patients before the end of the year. Walking distance and leg pain will be measured over the three-month duration of the trial. If a patient responds significantly to the treatment regimen, they may be recommended by their physician to continue the treatments past the three month time period established for the study.

Critical Limb Ischemia (CLI) is a severe blockage of the arteries that impairs blood flow to the hands, legs and lower extremities, resulting in insufficient levels of oxygen in the affected areas. While CLI is often caused by an acute condition, such as a blood clot, more often it is caused by a chronic condition, such as Peripheral Arterial Disease (PAD). An estimated 8.4 million Americans have peripheral arterial disease and 4.1 million have intermittent claudication.

'Based on recent clinical observations, we believe that Liprostin(TM) therapy may benefit individuals in earlier stages of peripheral vascular disease (PVD),'said Dr.


David Summers, Endovasc Chairman and CEO. 'The purpose of this study is to obtain safety and efficacy data for a proof of concept evaluation in PVD patients treated with a series of infusions of Liprostin(TM).'

'We are especially pleased that Dr. Mamuka Bokuchava will lead the study at this Center. His broad knowledge and experience in prostaglandin therapies will be important in the administration and evaluation of our trial,'commented Dr. Diane Dottavio, Endovasc V.P of Research and Development.

Liprostin(TM)

Endovasc's Liprostin is a liposome-encapsulated form of prostaglandin E-1 (PGE-1), that has been shown to be a potent vasodilator and platelet inhibitor, as well as an anti-inflammatory and anti-thrombotic agent. Liprostin has shown to improve the therapeutic index, positively impacting many areas of treatment, such as heart attacks, occlusive disease, ischemic ulcers, critical limb salvage, claudicants, and arthritis.